Metabolic Associated Fatty Liver Disease and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Patients

Tanta University

Status: Completed

Conditions: Metabolic Associated Fatty Liver Disease; Obese; Chronic Hepatitis B; Lean; Pancreatic Steatosis

Treatments: Diagnostic Test: Body mass index; Diagnostic Test: Waist Circumference; Device: Transient elastography; Device: Abdominal Ultrasound

Study type: Observational

Funder types: Other

Identifiers

NCT07175688

35454/4/22

Details and patient eligibility

About

This study aimed to evaluate the prevalence of metabolic associated fatty liver disease (MAFLD), fatty pancreas and hepatic fibrosis in obese and lean patients with chronic hepatitis B; either treatment naive or on treatment with first-line nucleos(t)ide analogs.

Full description

Hepatitis B virus (HBV) infection is one of the major etiologies of chronic liver disease. Pathologies caused by HBV infection range from chronic hepatitis, fibrosis, cirrhosis, to hepatocellular carcinoma (HCC).

Obesity is another significant health burden. Abdominal obesity is a type of obesity that is commonly associated with severe metabolic disorders and cardiovascular diseases.

Previous research has linked abdominal obesity to non-alcoholic fatty liver disease (NAFLD), insulin resistance, type 2 diabetes mellitus (T2DM), and even metabolic syndrome. In 2020, NAFLD was renamed metabolic-associated fatty liver disease (MAFLD) by a group of experts. MAFLD is defined by the presence of liver steatosis in addition to overweight/obesity, type 2 diabetes mellitus (T2DM), or metabolic dysregulation with at least two risk factors, such as an increased waist circumference, pre-diabetes, hypertension, hypertriglyceridemia, and low serum high-density lipoprotein (HDL)-cholesterol levels.

Enrollment: 217 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years or older.
• Both sexes.
• Chronic hepatitis B patients.

Exclusion criteria

• Hepatitis C virus (HCV) antibody positive.
• Hepatocellular carcinoma (HCC).
• Human immunodeficiency viruses (HIV).
• Pregnancy.

Trial design

217 participants in 2 patient groups

Group I

Description:

Obese chronic hepatitis B patients.

Treatment:

Device: Abdominal Ultrasound

Device: Transient elastography

Diagnostic Test: Waist Circumference

Diagnostic Test: Body mass index

Group II

Description:

Lean chronic hepatitis B patients.

Treatment:

Device: Abdominal Ultrasound

Device: Transient elastography

Diagnostic Test: Waist Circumference

Diagnostic Test: Body mass index